ライフサイエンスコーパス: salvage therapy

1 and therefore have limited ability to guide salvage therapy.

2 and help to expand its applicability beyond salvage therapy.

3 nal studies are needed to define the optimal salvage therapy.

4 ors (GCT) not amenable to cure with standard salvage therapy.

5 an early stage while it is amenable to local salvage therapy.

6 eve a favorable outcome to conventional-dose salvage therapy.

7 re is critical for selecting the appropriate salvage therapy.

8 ing these men poor candidates for local-only salvage therapy.

9 d local disease, precluding successful local salvage therapy.

10 regardless of initial treatment or manner of salvage therapy.

11 Vasopressin may be considered for salvage therapy.

12 ch trials are underway to elucidate the best salvage therapy.

13 an improved clinical response to amprenavir salvage therapy.

14 for a favorable outcome to conventional-dose salvage therapy.

15 higher than the mean at weeks 2, 4, and 8 of salvage therapy.

16 rcutaneous drainage failed required surgical salvage therapy.

17 compare this approach with conventional-dose salvage therapy.

18 neck dissection was a result of less use of salvage therapy.

19 tional patients (16%) are currently NED with salvage therapy.

20 onal patients (19.5%) are currently NED with salvage therapy.

21 and may improve the survival of patients on salvage therapy.

22 nuously NED and three are currently NED with salvage therapy.

23 dure on the likelihood of survival following salvage therapy.

24 first remission, and two were responsive to salvage therapy.

25 icant impact on the likelihood of successful salvage therapy.

26 patient developed acute leukemia after MOPP salvage therapy.

27 red following remission underwent successful salvage therapy.

28 nt (HCT) who subsequently received ibrutinib salvage therapy.

29 from steroid-refractory acute GvHD with MSC salvage therapy.

30 hese patients can be cured with conventional salvage therapy.

31 gh risk for recurrence and in candidates for salvage therapy.

32 the follow-up of PCa patients for tailoring salvage therapy.

33 dation extends time to progression requiring salvage therapy.

34 gly challenging largely due to resistance to salvage therapy.

35 r outcome was not influenced by the proposed salvage therapy.

36 lure of auto-SCT and in partial responses to salvage therapy.

37 se/persistence of infection, or the need for salvage therapy.

38 s (75%), were administered before IMiD-based salvage therapy.

39 previously untreated symptomatic CLL and as salvage therapy.

40 nded by differences in the use and timing of salvage therapy.

41 have a poor prognosis with conventional-dose salvage therapy.

42 ymal stem cell transplantation may emerge as salvage therapy.

43 , 34 patients had progressed and 17 required salvage therapy.

44 tients should respond favorably to DRV-based salvage therapy.

45 ed its recommendations on both frontline and salvage therapies.

46 ay improve the efficacy of genotype-assisted salvage therapies.

47 These findings might be used to select salvage therapies.

48 despite substantial use of novel-agent-based salvage therapies.

49 llow the response of patients to adjuvant or salvage therapies.

50 fy prostate cryoablation as both primary and salvage therapies.

51 ); however, they were more likely to receive salvage therapy (27.8% v 9.1%, P < .001).

52 ACVBP (54% vs 41%; P = .08), leading to more salvage therapy (37% vs 26%; P = .07) and lower event-fr

53 e that were CD38-positive had a mean time to salvage therapy 71 months shorter than patients who were

54 dioembolization with (90)Y microspheres as a salvage therapy after failed PRRT.

55 ory coccidioidomycosis were treated with V/C salvage therapy after failing conventional therapy consi

56 8 hrs; and 2) HBOC-201 could be an effective salvage therapy after severe neurotrauma or as a tempori

57 investigate the prevalence and influence of salvage therapy among patients with recurrent disease.

58 Hence, there is a need to develop effective salvage therapies and combine novel agents with standard

59 lengths of stay, but are at higher risk for salvage therapy and anastomotic strictures.

60 d were rendered continuously disease-free by salvage therapy and are alive.

61 cHL are being tested as part of primary and salvage therapy and are also highly relevant for HIV-cHL

62 ssion analysis, response to cytoreductive or salvage therapy and B symptoms at relapse were the most

63 s may thus be best strategically used before salvage therapy and before significant CD4 + T cell depl

64 ly a fraction of patients will be cured with salvage therapy and transplantation.

65 tors and mycophenolate mofetil are potential salvage therapies, and reagents such as recombinant inte

66 ails may have a response to and benefit from salvage therapies, and their prognosis is relatively goo

67 py with rituximab appears to be effective as salvage therapy, and ongoing clinical trials should dete

68 er, many of these children responded well to salvage therapy, and overall survival rates did not diff

69 to recommendations for staging, initial and salvage therapy, and surveillance.

70 rrence for soft tissue sarcomas, the role of salvage therapy, and the data in support of current surv

71 zed this group of patients for risk factors, salvage therapy, and treatment outcome.

72 relapse and survival status, and results of salvage therapy are reported.

73 eatment FDG PET performed during primary and salvage therapy are reviewed and management strategies c

74 hted or weighted drug-specific GSSs for each salvage therapy ARV.

75 l patients received proton beam therapy as a salvage therapy at the Helmholtz Zentrum Berlin between

76 In the absence of salvage therapy, at least three quarters of men will hav

77 cell cancer unlikely to be cured by standard salvage therapy but without proven refractoriness to che

78 ogress, perhaps partly due to more effective salvage therapies, but the FFS data also indicate improv

79 should optimize efficacy and tolerability of salvage therapy by stratifying patients according to ris

80 in the Obs arm received IFNalpha-containing salvage therapy compared with the HDI arm; this therapy

81 and the search for more effective and tissue-salvaging therapies continues.

82 kov model to simulate primary, adjuvant, and salvage therapy; disease recurrence; and survival in pat

83 juvant radiotherapy as compared with delayed salvage therapy do not exist.

84 Salvage therapies empirically conducted with 50 (n = 4),

85 Liver transplantation is an effective salvage therapy, even in the elderly, and AIH must be co

86 matologic malignancies for whom standard and salvage therapies failed were treated with LMB-2 at dose

87 nd is emerging as the most frequent cause of salvage therapy failure.

88 Effective salvage therapy followed the recognition of some of the

89 undred fourteen patients received subsequent salvage therapy following KI discontinuation with an ORR

90 rane oxygenation within the context of other salvage therapies for acute respiratory failure.

91 The assessment of new front-line and salvage therapies for adults and children were given top

92 at 300 to 1000 mg per day and was the first salvage therapy for 47 patients.

93 n elderly patients with comorbidities and as salvage therapy for achalasia.

94 domide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL).

95 status was associated with a shorter time to salvage therapy for disease progression (P < .001), perh

96 Salvage therapy for disseminated germ cell tumors of all

97 TI-CE is effective salvage therapy for GCT patients with poor prognostic fe

98 nazole, a new extended-spectrum triazole, as salvage therapy for IFIs in SOT recipients.

99 y of whole-brain radiation therapy (WBRT) as salvage therapy for immunocompetent patients who failed

100 However, SBRT is the preferred salvage therapy for local progression after RFA.

101 l evaluated scenarios, SBRT was preferred as salvage therapy for local progression after RFA.

102 th weekly (days eight and 15) vinorelbine as salvage therapy for metastatic breast cancer in anthracy

103 single-agent intravenous (IV) vinorelbine as salvage therapy for metastatic breast cancer.

104 idance about which therapy should be used as salvage therapy for patients after failure of a first-li

105 These results suggest an effective salvage therapy for patients for whom direct-acting anti

106 One potential use for amprenavir is as salvage therapy for patients for whom treatment that inc

107 ination with immunosuppressive agents, or as salvage therapy for patients who do not respond or lose

108 An analysis of salvage therapy for patients who relapsed on E1690 demon

109 hen R was included in the pretransplantation salvage therapy for patients with intermediate-grade NHL

110 Salvage therapy for patients with RP was delivered a med

111 Salvage therapy for progressive or recurrent primary cen

112 mbination voriconazole and caspofungin (V/C) salvage therapy for refractory coccidioidomycosis at two

113 ons are warranted to support the role of V/C salvage therapy for refractory coccidioidomycosis.

114 Their depletion has been proposed as salvage therapy for refractory disease.

115 ere estimated from the time of initiation of salvage therapy for refractory disease.

116 Conventional salvage therapy for relapsed follicular or low-grade lym

117 (50%) are alive, 6 in continuous CR, 2 after salvage therapy for relapsed or refractory disease, and

118 e needed to confirm the potential of MSCs as salvage therapy for steroid-refractory GvHD and to ident

119 usions (DLI) has been proven to be effective salvage therapy for the majority of patients who relapse

120 alovirus (CMV) infection is challenging, and salvage therapies, foscarnet, and cidofovir, have signif

121 ponsive to conventional rituximab-containing salvage therapy from 12 oncology-haematology centres in

122 ts is monthly observation with initiation of salvage therapy if and when there is serologic progressi

123 ort the use of autologous transplantation as salvage therapy if such patients achieve a subsequent CR

124 jury in pediatric and adult patients, and as salvage therapy in adult patients with acute respiratory

125 The role of salvage therapy in advanced disease remains undefined.

126 vide a substantial initial efficacy rate for salvage therapy in heavily antiretroviral-experienced HI

127 Pixantrone, given as a single-agent salvage therapy in heavily pretreated patients with rela

128 TIPS is highly effective as salvage therapy in high-risk patients with active varice

129 nt or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal can

130 red in combination were evaluated as initial salvage therapy in patients with relapsed or refractory

131 ailable data also support a limited role for salvage therapy in the setting of isolated local recurre

132 Risk factors for needing salvage therapy included reduced pulmonary diffusing cap

133 refore, the optimal candidate for local-only salvage therapy is a man whose pretreatment PSA velocity

134 d C-reactive protein > 45 mg/l on day 3) and salvage therapy is appropriate at this stage.

135 therapy to assess for recurrence and to plan salvage therapy is described.

136 cific antigen (PSA) levels at which targeted salvage therapy is effective.

137 icians to recognize that the primary goal of salvage therapy is to maximize disease-free survival and

138 5 years achieved a CR with either initial or salvage therapy; limited data suggest the same for patie

139 Single-drug maintenance after salvage therapy might be an attractive strategy to prolo

140 neration HIV-1 fusion inhibitor approved for salvage therapy of HIV-1-infected patients refractory to

141 -label trial that studied primary as well as salvage therapy of invasive mucormycosis showed efficacy

142 therapy cycle on arm C and, if necessary, as salvage therapy on all three treatment arms.

143 rty-five percent of patients did not require salvage therapies or colectomy during the first year pos

144 T], or no response to or relapse after first salvage therapy or beyond) leukaemia.

145 es (OR, 0.93; 95% CI, 0.87 to 0.99) and less salvage therapy (OR, 0.92; 95% CI, 0.88 to 0.98).

146 0; 95% CI, 1.04 to 1.87) and higher rates of salvage therapy (OR, 3.67; 95% CI, 2.81 to 4.81).

147 fection persistence/relapse, death, need for salvage therapy, or prosthesis removal occurred.

148 lyzed for the frequency of LRF over time and salvage therapy outcomes.

149 ho underwent allogeneic or autologous SCT as salvage therapy (P = .019).

150 ese situations, its use should be limited to salvage therapy pending the publication of controlled tr

151 -nine (94%) patients had cHL and 27 had >/=1 salvage therapy post-allo-HCT and prior to anti-PD-1 tre

152 ization, complications, lengths of stay, and salvage therapy rates for MIRP versus open radical prost

153 had a short survival period, irrespective of salvage therapy received; these patients have high unmet

154 as to investigate the effect of initiating a salvage-therapy regimen on resistant viruses in heavily

155 at baseline and at weeks 2, 4, and 8 of the salvage-therapy regimen.

156 se inhibitors may represent a potent drug in salvage therapy regimens after failure of an indinavir o

157 dy compared antiretroviral activity among 6 "salvage" therapy regimens.

158 Rational design of salvage therapies requires new methods to assess drug su

159 treatment-related mortality associated with salvage therapies, response rates of salvage regimens, a

160 le investigating the off-label use of BDQ as salvage therapy, seven of 13 patients with Mycobacterium

161 fosfamide, carboplatin, and etoposide)-based salvage therapy (ST) proceeded to high-dose chemoradioth

162 s of tumor-derived DNA in Rb eyes undergoing salvage therapy that have not been enucleated.

163 Mycophenolate mofetil is a possible salvage therapy that requires clinical trial, and liver

164 atients undergoing primary site resection as salvage therapy, the overall local control rate is 92.4%

165 darabine, cyclophosphamide, and rituximab as salvage therapy, there was no significant improvement in

166 lymphocyte infusions (DLIs) can be effective salvage therapy they are associated with severe graft-ve

167 uired to undergo a minimum of two courses of salvage therapy to determine chemosensitivity before tra

168 T]) is to implement a potentially beneficial salvage therapy to overcome possible morbidity/mortality

169 mor, 18 (53%) were successfully treated with salvage therapy via cystectomy, and 16 patients (16%) di

170 he 10-year actuarial survival rate following salvage therapy was 65% overall, 65% for patients in who

171 Salvage therapy was successful with second-line chemothe

172 The aim of salvage therapy was to achieve a complete remission (CR)

173 Salvage therapies were used more frequently after OBS th

174 , and favorable response to cytoreductive or salvage therapy were most predictive of superior FFP and

175 c features for response to conventional-dose salvage therapy were treated.

176 Factors predicting a good outcome after salvage therapy were young age (OS of 12% in patients yo

177 red for mixed chimerism and their utility as salvage therapy when given for relapse.

178 Optimal salvage therapy will depend on detailed results of rando

179 f positron emission tomography (PET)-adapted salvage therapy with brentuximab vedotin (BV) and augmen

180 PET-adapted sequential salvage therapy with brentuximab vedotin followed by aug

181 the feasibility and activity of PET-adapted salvage therapy with brentuximab vedotin, followed by au

182 leic acids in the AH from Rb eyes undergoing salvage therapy with intravitreous injection of melphala

183 es in similarly selected patients undergoing salvage therapy with one or two cycles of chemotherapy c

184 nd five of them remain free of disease after salvage therapy, with a median follow-up period of 79 mo